BioSpace News Archive

The Foundation for the National Institutes of Health has named Navdeep S. Chandel, Ph.D., of Northwestern University Feinberg School of Medicine, and Vamsi Mootha, M.D., of Howard Hughes Medical Institute and Harvard Medical School, as recipients of the 2023 Lurie Prize in Biomedical Sciences.

Momentum Biotechnologies, a leading contract research organization specializing in mass spectrometry-based native detection technologies, is pleased to announce the appointment of Harvard Medical School Professor Dr. Ying Lu to its Scientific Advisory Board.

Enliven Therapeutics, Inc. reported financial results for the second quarter ended June 30, 2023 and provided a business update.

Rain Oncology Inc., reports financial results for the second quarter ended June 30, 2023, and provides a corporate update.

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today reported financial results for the three and six months ended June 30, 2023 and provided a business update.

ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today reported financial results for the second quarter ended June 30, 2023, and provided an update on the Company’s portfolio of clinical programs in development.

Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended June 30, 2023, and provided a business update.

Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today reported financial results for the quarter ended June 30, 2023, and provided recent business highlights.

Talis Biomedical Corporation, a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, reported financial results for the second quarter ended June 30, 2023, and provided a business update.

Verrica Pharmaceuticals Inc. announced the presentation of lesion clearance data from Part 1 of an ongoing Phase 2 study of VP-315 for the treatment of basal cell carcinoma.